The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient's own immune cells on-site to kill cancer cells. This revolutionary immunomaterial technology was tested in a successful Phase I clinical trial and is currently licensed by Novartis as an immunotherapy to treat specific tumor types.
For more information, please visit: wyss.harvard.e...
Credit: Wyss Institute at Harvard University
22 авг 2024
